These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19539072)

  • 21. The incidence of clinically significant contrast-induced nephropathy following non-emergent coronary angiography.
    Weisbord SD; Hartwig KC; Sonel AF; Fine MJ; Palevsky P
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):879-85. PubMed ID: 18412255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Transient or Persistent Contrast-induced Nephropathy on Long-term Mortality After Elective Percutaneous Coronary Intervention.
    Abe M; Morimoto T; Nakagawa Y; Furukawa Y; Ono K; Kato T; Kadota K; Ando K; Ishii M; Masunaga N; Akao M; Kimura T
    Am J Cardiol; 2017 Dec; 120(12):2146-2153. PubMed ID: 29106836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI.
    Wickenbrock I; Perings C; Maagh P; Quack I; van Bracht M; Prull MW; Plehn G; Trappe HJ; Meissner A
    Clin Res Cardiol; 2009 Dec; 98(12):765-72. PubMed ID: 19851800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
    Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
    Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
    Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
    Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of iso-osmolar contrast use in emergent percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Kanei Y; Ayabe K; Ratcliffe J; Vales L; Nakra N; Friedman P; Fox J
    J Invasive Cardiol; 2011 Nov; 23(11):448-50. PubMed ID: 22045075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
    Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
    J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty.
    Song T; Song M; Ge Z; Li Y; Shi P; Sun M
    J Interv Cardiol; 2017 Jun; 30(3):281-285. PubMed ID: 28421628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.
    Li Y; Liu Y; Shi D; Yang L; Liang J; Zhou Y
    Angiology; 2016 Feb; 67(2):139-45. PubMed ID: 25843952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Slocum NK; Grossman PM; Moscucci M; Smith DE; Aronow HD; Dixon SR; Share D; Gurm HS
    Am Heart J; 2012 May; 163(5):829-34. PubMed ID: 22607861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
    Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
    Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease.
    Toprak O; Cirit M; Yesil M; Bayata S; Tanrisev M; Varol U; Ersoy R; Esi E
    Nephrol Dial Transplant; 2007 Mar; 22(3):819-26. PubMed ID: 17090607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
    Kim SJ; Choi D; Ko YG; Kim JS; Han SH; Kim BK; Kang SW; Hong MK; Jang Y; Choi KH; Yoo TH
    Am J Cardiol; 2011 Oct; 108(8):1086-91. PubMed ID: 21791335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Value of Gamma-Glutamyl Transferase Levels for Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention.
    Oksuz F; Yarlioglues M; Cay S; Celik IE; Mendi MA; Kurtul A; Cankurt T; Kuyumcu S; Canpolat U; Turak O
    Am J Cardiol; 2015 Sep; 116(5):711-6. PubMed ID: 26116992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.
    Miner SE; Dzavik V; Nguyen-Ho P; Richardson R; Mitchell J; Atchison D; Seidelin P; Daly P; Ross J; McLaughlin PR; Ing D; Lewycky P; Barolet A; Schwartz L
    Am Heart J; 2004 Oct; 148(4):690-5. PubMed ID: 15459602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.